.16 All end points
were analyzed for olaparib doses combined and individually versus PLD.
Disease assessments were performed at baseline and every 8 weeks until
progression, using computed tomography and/or magnetic resonance imaging
and serum CA-125 measurements. Patients who discontinued treatment
before disease progression had disease assessments until progression or initiation
of an alternative anticancer treatment. Centrally reviewed tumor assessments
for all patients with RECIST scans were used for sensitivity analyses.
Safety and tolerability were evaluated at baseline and at least every 4 weeks, as
assessed by AEs and changes in laboratory parameters according to Common
Terminology Criteria for Adverse Events (CTCAE).17